Recruiting
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
I6T-MC-AMAH - ClinicalTrials.gov - NCT03556202
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
How long will I be in the trial?
The study will last about 220 weeks and may include up to 23 visits.
Recruiting
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
I6T-MC-AMAH - ClinicalTrials.gov - NCT03556202
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
How long will I be in the trial?
The study will last about 220 weeks and may include up to 23 visits.
Key Requirements
Age :
18+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have completed the last visit of an eligible study period of originating study
Participants must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential
Participants must NOT
Participants must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, liver, kidney, gastrointestinal, endocrine, blood, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study
Participants must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab
Trial Summary
Conditions the trial is for
Psoriasis
What the trial is testing?
Mirikizumab
Could I receive a Placebo?
no
Enrollment Goal
1816
Trial Dates
September 2018 - May 2024
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
18+
Sex
All
Participants must
Participants must have completed the last visit of an eligible study period of originating study
Participants must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential
Participants must NOT
Participants must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, liver, kidney, gastrointestinal, endocrine, blood, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study
Participants must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab
Trial Summary
Conditions the trial is for
Psoriasis
What the trial is testing?
Mirikizumab
Could I receive a Placebo?
no
Enrollment Goal
1816
Trial Dates
September 2018 - May 2024
Trial Phase
3
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Psoriasis Resources
